Open-angle Glaucoma
📧 Sign up to get email alerts when something new happens for Open-angle Glaucoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2020-11-03FDA Approved: DURYSTA — Supplemental Application (Allergan, Inc.)
The FDA approved a supplemental application for Durysta (bimatoprost) submitted by Allergan, Inc. This marks approval of an add-on to the ND…
-
CLINICAL_TRIALS trial_result · 2020-10-23Clinical Trial Update: A Phase IIb Safety and Efficacy Study of DE-126 Ophthalmic Solution in Primary Open-Angle Glaucoma or Ocular Hypertension- Angel Study [Phase 2]
Phase IIb study of DE-126 ophthalmic solution in open-angle glaucoma or ocular hypertension completed with posted results.
-
FDA approval · 2020-10-22FDA Approved: TIMOLOL MALEATE OPHTHALMIC GEL FORMING SOLUTION, 0.25% — Original Application (Alembic Pharmaceuticals Inc.)
Alembic Pharmaceuticals received FDA approval for timolol maleate ophthalmic gel-forming solution in 0.25% (and 0.5%) strengths via original…
-
CLINICAL_TRIALS trial_result · 2020-10-19Clinical Trial Update: Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan [Phase 2]
Phase 2 trial evaluating the efficacy and systemic safety of netarsudil at 0.01%, 0.02%, and 0.04% versus placebo in open-angle glaucoma or …
-
CLINICAL_TRIALS trial_result · 2020-10-09Clinical Trial Update: Intraocular Pressure (IOP) Patterns in Fast Versus Slow Visual Field (VF) Progression Patients [NA]
A terminated clinical trial assessing intraocular pressure patterns in fast versus slow visual field progression in primary open-angle glauc…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-10-08Clinical Trial Update: RCT to Investigate if Prostaglandin Analogue Drops Increase the Risk of Cystoid Macular Oedema After Cataract Surgery. [Phase 2]
Phase 2 randomized trial assessing whether prostaglandin analogue drops increase the risk of cystoid macular edema after cataract surgery.
-
FDA approval · 2020-09-29FDA Approved: LUMIGAN — Supplemental Application (Allergan, Inc.)
FDA approved a supplemental application for LUMIGAN (bimatoprost) from Allergan, Inc.
-
FDA approval · 2020-09-03FDA Approved: TRAVOPROST — Supplemental Application (Apotex Corp.)
FDA approved a supplemental application from Apotex Corp. for Travoprost (ophthalmic) under an ANDA, granting additional regulatory clearanc…
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma [Phase 2]
Phase 2 dose-finding trial comparing latanoprost to a novel glaucoma treatment, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: A Phase 2, Dose Finding Study of PF-03187207 in Patients With Primary Open Angle Glaucoma or Ocular Hypertension. [Phase 2]
Phase 2 dose-finding trial of PF-03187207 in primary open-angle glaucoma or ocular hypertension completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-04Clinical Trial Update: Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution Once Daily and Twice Daily in Subjects With Primary Open-Angle Glaucoma SPECTRUM 6 [Phase 2]
Phase 2 trial assessing safety and efficacy of DE-117 ophthalmic solution administered once daily and twice daily in primary open-angle glau…
-
CLINICAL_TRIALS trial_result · 2020-07-02Clinical Trial Update: Subconjunctival Versus Direct Mitomycin C in Trabeculectomy [Phase 4]
A Phase 4 trial comparing subconjunctival versus direct mitomycin C in trabeculectomy for open-angle glaucoma has completed with results pos…
-
CLINICAL_TRIALS trial_result · 2020-06-25Clinical Trial Update: A Clinical Study to Evaluate the Efficacy and Safety of CKD-351 [Phase 2]
Phase 2 clinical trial evaluating the efficacy and safety of CKD-351 for primary open angle glaucoma and ocular hypertension.
-
CLINICAL_TRIALS trial_result · 2020-06-04Clinical Trial Update: Dose-Ranging Study of the Bimatoprost Ocular Insert [Phase 2]
Phase 2 dose-ranging study of the bimatoprost ocular insert for open-angle glaucoma and ocular hypertension completed.
-
FDA approval · 2020-05-28FDA Approved: DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE OPHTHALMIC SOLUTION — Original Application (Micro Labs Limited)
FDA approved Micro Labs Limited's generic dorzolamide hydrochloride and timolol maleate ophthalmic solution. It is indicated for reduction o…
-
CLINICAL_TRIALS trial_result · 2020-04-24Clinical Trial Update: Efficacy and Safety Study of Bimatoprost Sustained-Release (SR) in Participants With Open-angle Glaucoma or Ocular Hypertension [Phase 3]
Phase 3 trial update on the efficacy and safety of bimatoprost sustained-release (SR) for open-angle glaucoma or ocular hypertension has com…
-
FDA label_change · 2020-04-02FDA Approved: TRAVATAN Z — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for TRAVATAN Z (travoprost) from Novartis Pharmaceuticals Corporation, resulting in a labeling c…
-
CLINICAL_TRIALS trial_result · 2020-04-02Clinical Trial Update: Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose [Phase 4]
Phase 4 trial comparing Monoprost with Lumigan formulations for safety and efficacy in primary open angle glaucoma and ocular hypertension; …
-
CLINICAL_TRIALS trial_result · 2020-03-30Clinical Trial Update: Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension [Phase 1, Phase 2]
Phase 1/2 trial update on a new ophthalmic formulation of bimatoprost for open-angle glaucoma and ocular hypertension; results have been pos…
-
FDA approval · 2020-03-25FDA Approved: DORZOLAMIDE HYDROCHLORIDE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for dorzolamide hydrochloride from Sandoz Inc., granting regulatory clearance for changes to thi…
-
FDA approval · 2020-03-04FDA Approved: DURYSTA — Original Application (Allergan, Inc.)
FDA approved DURYSTA (bimatoprost intracameral implant) from Allergan as the original approval for reducing intraocular pressure in adults w…
-
CLINICAL_TRIALS trial_result · 2020-03-04Clinical Trial Update: Comparing the Effectiveness of Phacoemulsification + ECP Laser and Phacoemulsification Alone for Glaucoma Patients [Phase 4]
A Phase 4 clinical trial comparing phacoemulsification with endoscopic cyclophotocoagulation (ECP) laser versus phacoemulsification alone in…
-
FDA approval · 2020-02-19FDA Approved: LATANOPROST — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for a generic latanoprost product from Sandoz Inc., enabling its market availability. The approv…
-
CLINICAL_TRIALS trial_result · 2020-01-30Clinical Trial Update: Educational Intervention to Adopt SLT as First-Line Glaucoma Treatment [NA]
A completed clinical trial evaluating an educational intervention to adopt selective laser trabeculoplasty (SLT) as first-line treatment for…
-
FDA approval · 2020-01-27FDA Approved: TRAVOPROST — Supplemental Application (Apotex Corp.)
The FDA approved a supplemental application from Apotex Corp. for a generic travoprost product.